{
  "id": 10301383,
  "title": "Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests",
  "url": "https://urgent.news/2026/09/27/millions-more-people-with-overweight-could-benefit-from-glp-1-drugs",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-27T22:10:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-millions-people-overweight-benefit-glp.html"
  },
  "original_language": "en",
  "account": "A study presented at the European Association for the Study of Diabetes in Milan suggests that millions more overweight individuals could benefit from GLP-1 receptor agonist drugs (GLP1-RAs) to protect their heart health. Currently, these drugs are approved for weight loss in adults with a BMI of 30 or higher or a BMI of 27 plus a weight-related health condition. However, a Danish analysis of data from the U.K. and Denmark found that approximately half of people in the overweight range (BMI 25-26.9) have elevated remnant cholesterol and/or low-grade inflammation, which increases their risk of heart disease. These participants were not previously eligible for GLP-1 RAs but had a similar risk of coronary heart disease as those eligible for the drugs. The study suggests extending the indication for GLP-1 RAs to this group, as clinical trials are needed to confirm whether treatment would reduce their risk.",
  "summary": "New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor agonists (GLP1-RAs) to millions more people to protect their heart health.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}